ACPR/Treatment Success (%, 95% CL)
| | | | |
ITT
|
181 [90.0 (85.9–94.2)]
|
180 [90.0 (85.8–94.2)]
|
0.99
|
361 [90.0 (86.7–92.8)]
|
Modified ITT
|
181 [93.3 (89.8–96.8)]
|
180 [94.7 (91.6–97.9)]
|
0.55
|
361 [94.0 (91.1–96.2)]
|
Per Protocol
|
181 [96.3 (93.6–99.0)]
|
180 [97.3 (95.0–99.6)]
|
0.58
|
361 [96.8 (94.4–98.3)]
|
Late Clinical Failure-LCF (%, 95% CL)
| | | | |
ITT
|
4 [2.0 (0.1–3.9)]
|
1 [0.5 (0.5–1.5)]
|
0.18
|
5 [1.2 (0.4–2.9)]
|
Modified ITT
|
4 [2.1 (0.1–4.1)]
|
1 [0.5 (0.5–1.6)]
|
0.18
|
5 [1.3 (0.4–3.0)]
|
3. Per Protocol
|
4 [2.1 (0.1–4.2)]
|
1 [0.5 (0.5–1.6)]
|
0.18
|
5 [1.3 (0.4–3.1)]
|
Late Parasitological Failure-LPF (%, 95% CL)
| | | | |
ITT
|
3 [1.5 (0.2–3.2)]
|
4 [2.0 (0.1–3.9)]
|
0.70
|
7 [1.7 (0.7–3.6)]
|
Modified ITT
|
3 [1.6 (0.2–3.3)]
|
4 [2.1 (0.1–4.1)]
|
0.68
|
7 [1.8 (0.7–3.7)]
|
Per Protocol
|
3 [1.6 (0.2–3.4)]
|
4 [2.2 (0.1–4.3)]
|
0.69
|
7 [1.9 (0.8–3.8)]
|
“Other Failures” (%, 95% CL)
| | | | |
ITT
|
13 [6.5 (3.1–9.9)]
|
15 [7.5 (3.8–11.1)]
|
0.68
|
28 [7.0 (4.7–9.9)]
|
Modified ITT
|
6 [3.1 (0.7–5.5)]
|
5[2.6 (0.4–4.9)]
| |
11 [2.9 (1.4–5.1)]
|
Per Protocol
|
0
|
0
|
0.79
|
0
|